Potential role of ferroptosis in sterile acute lung injury induced by a non-hypoxic ischemia-reperfusion insult.

Authors

Farzaneh Kianian, Xiaoli Tian, Daisuke Maruyama, Arun Prakash

Published in

Iranian journal of basic medical sciences. Volume 29. Issue 9. Pages 1355-1360.

Abstract

Ferroptosis, a regulated form of necrotic cell death, is implicated in the pathogenesis of hypoxic lung ischemia-reperfusion injury (LIRI). However, its role in non-hypoxic LIRI, which occurs in common clinical conditions such as trauma and pulmonary embolism, remains unclear. Given that ferroptosis has been implicated in sterile inflammation and lipid peroxidation is a hallmark of this process, this study aimed to investigate the potential role of ferroptosis in inflammatory responses during non-hypoxic LIRI.
Non-hypoxic LIRI was induced in C57BL/6 mice by occluding the left pulmonary artery for 1 hr, followed by 30 min of reperfusion. The treatment group received liproxstatin-1 (Lip-1; 10 mg/kg, IP) 1 hr before surgery. IL-6 levels in plasma and lung tissue were measured by ELISA. For the in vitro model, normal human bronchial epithelial (NHBE) cells were exposed to nutritional ischemia for 1 hr and then reperfused for 2 hr. Cells were pretreated with Lip-1 (200 nM) 12 hr before ischemia. CXCL1 release was measured by ELISA, and lipid reactive oxygen species (ROS) accumulation was assessed by BODIPY 581/591 C11 fluorescence.
Non-hypoxic LIRI markedly increased IL-6 levels in plasma and lung tissue, as well as CXCL1 levels and lipid ROS accumulation in NHBE cells. Pretreatment with Lip-1 significantly reduced these inflammatory responses and lipid ROS accumulation compared with untreated LIRI.
Our findings suggest that ferroptosis-associated lipid peroxidation is associated with sterile inflammatory responses during non-hypoxic LIRI in both systemic and epithelial compartments. Lip-1 attenuated these responses, highlighting a potential strategy for non-hypoxic LIRI.

PMID:
42703244
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.